J Mitchell, C Bradley - Health and quality of life outcomes, 2006 - biomedcentral.com Address: Department of Psychology, Royal Holloway, University of London, Egham,
Surrey, TW20 0EX, UK Email: Jan Mitchell* - j.mitchell@rhul.ac.uk; Clare Bradley
- c.bradley@rhul.ac.uk * Corresponding author ... Abstract Background: ... Cited by 30 - Related articles - View as HTML - All 9 versions
AW Hewitt, VS Jeganathan, JE Kidd, K … - Graefe's Archive for Clinical and Experimental …, 2006 - Springer Abstract Background: Photody- namic therapy (PDT) has been used in the treatment
of choroidal neovascu- larisation secondary to age-related macular degeneration
(AMD). This study prospectively investigated pa- tients' subjective change ... Cited by 12 - Related articles - BL Direct - All 4 versions
- ►prsjournal.com B Morris, F Imrie, AM Armbrecht, B Dhillon - British Medical Journal, 2007 - pmj.bmj.com Age-related macular degeneration (AMD) is the commonest cause of blindness in
the population over 60 years of age and accounts for over 50% of those
registered blind in the UK. The incidence is increasing and as older ... Cited by 12 - Related articles - BL Direct - All 6 versions
G Donati - Ophthalmologica, 2007 - content.karger.com The cornerstone of pharmacotherapeutic treatment for age-related macular
degeneration (AMD) is photodynamic therapy with verteporfin. The recently
approved pegaptanib sodium, which targets vascular endothelial growth ... Cited by 9 - Related articles - BL Direct - All 4 versions
- ►qut.edu.au [PDF] JE Lovie-Kitchin, B Feigl, 2008 - eprints.qut.edu.au A paper published by the first author in this journal almost 25 years ago 1 on
the assessment of 'senile macular degenera- tion' reviewed the standard tests of
clini- cal vision according to three criteria: 1. Were the tests effective ... Cited by 7 - Related articles - All 5 versions
RP Finger, M Fleckenstein, FG Holz, HPN … - Quality of Life Research, 2008 - Springer Abstract Purpose Age-related macular degeneration (AMD) has a considerable
impact on older adults' independence and autonomy. Recently, patient reported
outcomes (PROs) such as QoL have been met with increasing interest by the ... Cited by 5 - Related articles - BL Direct - All 2 versions
- ►prsjournal.com C Incorvaia, C Campa, F Parmeggiani, M … - Retina, 2008 - journals.lww.com Purpose: To evaluate the 12-month visual outcome of photodynamic therapy with
verteporfin (PDT-V) for patients with subfoveal choroidal neovascularization
(CNV) secondary to age-related macular degeneration and to verify the ... Cited by 4 - Related articles - BL Direct - All 3 versions
M Lüke, F Ziemssen, KU Bartz-Schmidt, F … - Graefe's Archive for Clinical and Experimental …, 2007 - Springer Abstract Purpose To assess visual function and its effects on vision- targeted,
health-related quality of life (QOL) of patients with neovascular age-related
macular degeneration (AMD) treated with photodynamic therapy (PDT) or full ... Cited by 3 - Related articles - BL Direct - All 2 versions
